Location History:
- Santa Monica, CA (US) (2014)
- Torrance, CA (US) (2022)
Company Filing History:
Years Active: 2014-2022
Title: Kevin W Bruhn: Innovator in Immunology and Antibody Research
Introduction
Kevin W Bruhn is a notable inventor based in Santa Monica, California, recognized for his contributions to immunology and antibody research. With two patents to his name, he remains at the forefront of developing innovative solutions that address challenges in combating infections and enhancing immune responses.
Latest Patents
Among his latest patents, Kevin has developed "Antibody binding agents that bind and uses thereof." This invention presents compositions comprising antibody binding agents that specifically bind to and inhibit or block infections, showcasing significant potential in therapeutic applications. Additionally, his other patent, "Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists," provides compositions designed to induce an immune response in vertebrate hosts against protozoan parasites. This innovation includes a protozoan parasite with psoralen-modified DNA, killed but still metabolically active, along with Toll-like receptor agonists.
Career Highlights
Kevin W Bruhn is associated with the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, where he contributes to groundbreaking research in immune responses and vaccine development. His work focuses on utilizing novel methodologies to enhance the effectiveness of vaccines against parasitic infections.
Collaborations
Throughout his career, Kevin has collaborated with esteemed colleagues in his field, including Noah Ames Craft and Ron A Birnbaum. These collaborations enrich his research efforts and foster advancements in the understanding and treatment of infectious diseases.
Conclusion
Kevin W Bruhn exemplifies the spirit of innovation in the realm of immunology. His patents demonstrate a commitment to creating impactful solutions, ultimately contributing to the health and wellbeing of populations affected by infections. As he continues his work at the Los Angeles Biomedical Research Institute, the scientific community eagerly anticipates further advancements from his endeavors.